XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$28.19 USD
-1.66 (-5.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.49 +0.30 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 101 - 120 ( 332 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
XOMA on Track With Its New Licensing Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
New Management, New Strategy: Low Risk, High Reward; Initiating With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financial Update; $10 Million Milestone Payment Expected This Quarter; Reiterate NEUTRAL and $9 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financial Update; $10 Million Milestone Payment Anticipated This Quarter; Reiterate NEUTRAL and $9 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q4/FY16 Update: New Strategic Approach Reduces Cash Burn and Focuses Solely on Royalty Revenues; Reiterate NEUTRAL but Reducing PT to $9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Single Dose 358 Trial Supports Previous Interim Positive Proof-of-Concept in CHI and PBS; Reiterate NEUTRAL and $14 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q3 Update: Despite Pipeline Progress, Near-Term Financing Overhang on the Stock; Downgrading to NEUTRAL and Reducing PT to $14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q3 Update: Despite Pipeline Progress, Near-Term Financing Overhang on the Stock; Downgrading to NEUTRAL and Reducing PT to $14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Progress with XOMA 358 for CHI in Europe; Price Target Moves to $17 from $1.42 from Adjustments for 1:20 Reverse Stock Split; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L